1. Home
  2. FOR vs CRVS Comparison

FOR vs CRVS Comparison

Compare FOR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Forestar Group Inc

FOR

Forestar Group Inc

HOLD

Current Price

$25.96

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

Logo Corvus Pharmaceuticals Inc.

CRVS

Corvus Pharmaceuticals Inc.

HOLD

Current Price

$12.17

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FOR
CRVS
Founded
2005
2014
Country
United States
United States
Employees
406
N/A
Industry
Real Estate
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.2B
IPO Year
2007
2016

Fundamental Metrics

Financial Performance
Metric
FOR
CRVS
Price
$25.96
$12.17
Analyst Decision
Buy
Strong Buy
Analyst Count
3
6
Target Price
$32.67
$30.17
AVG Volume (30 Days)
115.1K
1.6M
Earning Date
04-21-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
48.04
EPS
0.93
N/A
Revenue
$1,662,400,000.00
N/A
Revenue This Year
$0.34
N/A
Revenue Next Year
$7.73
N/A
P/E Ratio
$27.16
N/A
Revenue Growth
10.14
N/A
52 Week Low
$18.50
$3.38
52 Week High
$30.74
$26.95

Technical Indicators

Market Signals
Indicator
FOR
CRVS
Relative Strength Index (RSI) 44.37 36.24
Support Level $25.36 $6.65
Resistance Level $25.97 $19.21
Average True Range (ATR) 0.87 1.04
MACD -0.23 -0.44
Stochastic Oscillator 30.30 13.81

Price Performance

Historical Comparison
FOR
CRVS

About FOR Forestar Group Inc

Forestar Group Inc is a residential lot development company engaged in land acquisition and development for the sale of finished single-family residential lots to local, regional, and national homebuilders. The company operates through a single real estate segment, which acquires land, installs infrastructure for residential communities, and generates all revenue from lot sales. Its communities mainly support entry-level, first-time move-up, and active-adult homes, with certain communities also marketed to build-to-rent operators. The company generally invests in entitled, short-duration projects that can be developed in phases to align lot production with market demand and support efficient capital deployment.

About CRVS Corvus Pharmaceuticals Inc.

Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.

Share on Social Networks: